Skip to main content

Read the latest news about research and scientific resultats on Alzheimer's disease at the Barcelonaβeta Brain Research Center (BBRC).

06 Apr | 2021

BBRC researchers discovered new benefits of blue fish consumption in people at risk of developing Alzheimer's disease

A study led by the BBRC has found that people without cognitive problems but with a higher genetic risk of developing Alzheimer's have certain areas of the brain more resilient to the disease if they are accustomed to consuming a nutrient provided by blue fish.

11 Mar | 2021

European researchers improve the sensitivity to detect the early stages of Alzheimer's disease

A team of researchers from the AMYPAD consortium, led at BBRC, showed that the visual assessment used in clinical practice to evaluate amyloid PET images is sensitive to detecting the earliest stages of Alzheimer’s disease, and suggests a method to classify the extent of the pathology in the brain.

16 Feb | 2021

Spanish scientists uncover early links between cardiovascular risk and brain metabolism

Investigators at the CNIC, in partnership with the BBRC, have discovered a link between brain metabolism, cardiovascular risk, and atherosclerosis during middle age, years before symptoms appear

23 Dec | 2020

José Luis Molinuevo has been named on the Highly Cited Researchers 2020 list

The scientific publications of the promoter of the BBRC Alzheimer's Prevention Program are among the 1% of the most cited in its field in Web of Science.

10 Nov | 2020

BBRC researchers identify new tau biomarkers to detect the preclinical phase of Alzheimer's disease

An international team of researchers, led at the BBRC, has discovered that a series of biomarkers recently described to detect the most advanced phase of Alzheimer's can also detect the preclinical phase of the disease in the cerebrospinal fluid and plasma.

28 Sep | 2020

Avalanche of data against Alzheimer's

The digitization of the data collected in our studies allows us to accelerate our research, improve its integrity and make it available to researchers around the world.

16 Sep | 2020

The FDA accepts license application for aducanumab, the first possible disease modifying drug for Alzheimer’s

Dr José Luis Molinuevo comments the possible approval of Biogen’s new treatment, in an interview for the podcast Saving Minds.

04 Sep | 2020

Marc Suárez-Calvet is awarded an ERC Starting Grant to identify age-related blood factors as a therapeutic target for Alzheimer’s disease

The research, endowed with nearly 1.5 milion euros, will provide a new therapeutic target for Alzheimer's disease, in which age is the most important risk factor